Company news
Immunic, Inc. (NASDAQ:IMUX) news
Every Immunic, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Immunic Appoints Chitrang Davé as Chief Data and Digital Officer
September 1, 2026
Immunic, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update
August 11, 2026
Immunic to Participate in Investor Conferences in July
July 9, 2026
Immunic to Participate in Investor, Industry and Scientific Conferences in June
June 10, 2026
Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the CMSC Annual Meeting 2026, Reinforcing Its Poten...
May 28, 2026
Immunic Appoints Distinguished Biopharmaceutical Executive Erik Lundgren as Chief Executive Officer
May 27, 2026
Immunic Appoints Seasoned Biopharmaceutical Executive Michael W. Bonney as Chair of the Board of Directors
May 19, 2026
Immunic, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 13, 2026
Immunic to Participate in Investor and Medical Conferences in May
April 30, 2026
Immunic Appoints Accomplished Biopharmaceutical Executive Michael A. Panzara, M.D., M.P.H., as Chief Medical Officer
April 28, 2026
Immunic, Inc. Announces 1-for-10 Reverse Stock Split
April 23, 2026
Immunic to Participate in Scientific and Medical Conferences in April
April 9, 2026
Immunic Regains Compliance with Nasdaq Minimum Bid Price Requirement
April 1, 2026
Immunic Strengthens Its Board of Directors with the Appointment of Seasoned Biopharmaceutical Executive Jon Congleton
March 31, 2026
Immunic Announces Grant of Key European Patent Protecting Relevant Dosing Regimens for Vidofludimus Calcium
March 10, 2026
Immunic to Participate in Investor Conferences in March
March 3, 2026
Immunic, Inc. Reports Year-End 2025 Financial Results and Provides Corporate Update
February 26, 2026
Immunic Announces Closing of Oversubscribed Private Placement Financing
February 17, 2026
Immunic Announces Oversubscribed Private Placement of up to USD 400 Million to Accelerate Transformation into Commercial-Stage Company
February 13, 2026
Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the ACTRIMS Forum 2026, Reinforcing Its Potential i...
February 4, 2026
Immunic Highlights 2025 Accomplishments and Upcoming Milestones
January 7, 2026
Immunic to Participate in the 8th Annual Evercore ISI Healthcare Conference in December
November 26, 2025
Immunic, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update
November 13, 2025
Immunic to Participate in Industry and Investor Conferences in November
October 29, 2025
Immunic to Participate in Scientific and Investor Conferences in October
October 1, 2025
Immunic Presented Key Vidofludimus Calcium Data at the 41st Congress of ECTRIMS, Highlighting Its Potential in Multiple Sclerosis
September 25, 2025
Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dose Strengths in Progressive Multiple Sc...
September 9, 2025
Immunic to Participate in Investor and Scientific Conferences in September
September 4, 2025
Immunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update
August 7, 2025
Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitt...
June 24, 2025
Immunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining Positi...
June 5, 2025
Immunic, Inc. Announces Closing of Oversubscribed $65 Million Underwritten Public Offering
June 3, 2025
Immunic to Participate in Investor, Scientific and Industry Conferences in June
June 2, 2025
Immunic, Inc. Announces Pricing of Oversubscribed $65 Million Underwritten Public Offering
May 29, 2025
Immunic, Inc. Announces Proposed Public Offering
May 28, 2025
Immunic to Participate in Scientific and Industry Conferences in May
May 2, 2025
Immunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis Patients fro...
April 30, 2025
Immunic, Inc. Announces Closing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments
April 10, 2025
Immunic, Inc. Announces Pricing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments
April 9, 2025
Immunic, Inc. to Participate in Scientific and Industry Conferences in April
April 1, 2025
Immunic to Participate in Scientific and Investor Conferences in March
March 3, 2025
Immunic Presents Key Vidofludimus Calcium Data at the ACTRIMS Forum 2025, Highlighting Its Potential in Multiple Sclerosis
February 26, 2025
Immunic's Oral IMU-856 Demonstrated Dose-Dependent Increase of GLP-1 in Celiac Disease Patients and Corresponding Effects in Preclinical ...
February 20, 2025
Immunic to Participate in Investor and Scientific Conferences in February
February 4, 2025
Immunic Highlights 2024 Accomplishments and Upcoming Milestones
January 7, 2025
Immunic, Inc. to Participate in Investor Conference in December
November 26, 2024
Immunic Announces Publication of Data From Phase 1/1b Clinical Trial of IMU-856 in the Peer Reviewed Journal, The Lancet Gastroenterology...
November 13, 2024
Immunic to Present at the November 21st Virtual Investor Summit Microcap Event
November 11, 2024
Immunic, Inc. Reports Third Quarter 2024 Financial Results and Provides Corporate Update
November 7, 2024
Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update
October 31, 2024